0000950170-24-071393.txt : 20240610
0000950170-24-071393.hdr.sgml : 20240610
20240610165850
ACCESSION NUMBER: 0000950170-24-071393
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240606
FILED AS OF DATE: 20240610
DATE AS OF CHANGE: 20240610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Moukheibir Catherine
CENTRAL INDEX KEY: 0001772130
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34620
FILM NUMBER: 241033559
MAIL ADDRESS:
STREET 1: C/O IRONWOOD PHARMACEUTICALS, INC.
STREET 2: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
FORMER NAME:
FORMER CONFORMED NAME: Moukheibir Catherine Michener
DATE OF NAME CHANGE: 20190328
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001446847
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 043404176
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 617-621-7722
MAIL ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
ownership.xml
4
X0508
4
2024-06-06
0001446847
IRONWOOD PHARMACEUTICALS INC
IRWD
0001772130
Moukheibir Catherine
C/O IRONWOOD PHARMACEUTICALS, INC.
100 SUMMER STREET, SUITE 2300
BOSTON
MA
02110
true
false
false
false
false
Class A Common Stock
2024-06-06
4
S
false
44426
6.36
D
84207
D
Class A Common Stock
2024-06-07
4
S
false
35574
6.61
D
48633
D
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.43, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.56 to $6.65, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ Brian Tessler, Attorney-in-Fact
2024-06-10